Study on parameters and efficacy of treatment with denosumab for bone metastases of prostate cancer

Study on parameters and efficacy of treatment with denosumab for bone metastases of prostate cancer - Study on parameters and efficacy of treatment with denosumab for bone metastases of prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009985

Enrollment

Registered

2013-02-15

Start date

2013-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastatic prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: castration resistant prostate cancer (CRPC) with bone metastasis.

Exclusion criteria

Exclusion criteria: 1)prostate cancer without bone metastasis 2)Prior treatment with surgery for bone metastasis before study start 3)Prior treatment with bisphosphonates before study start, and during treatment with zoledronic acid 4)Prior treatment with radiation therapy

Design outcomes

Primary

Measure	Time frame
The rate of change of BSI and the bone turnover markers and PSA by the treatment	—

Secondary

Measure	Time frame
The correlation between rate of change of BSI and the bone turnover markers and PSA and skeletal related event by the treatment	—

Countries

Japan

Contacts

Public ContactKensaku Seike

Gifu University Hospital Department of Urology

058-230-6000

Outcome results